249 related articles for article (PubMed ID: 11801704)
1. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
Coover LR; Silberstein EB; Kuhn PJ; Graves MW
J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
[TBL] [Abstract][Full Text] [Related]
3. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
[TBL] [Abstract][Full Text] [Related]
4. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
5. External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.
Jørgensen HB; Høilund-Carlsen PF; Nielsen VE
Scand J Clin Lab Invest; 2006; 66(6):509-16. PubMed ID: 17000558
[TBL] [Abstract][Full Text] [Related]
6. Estimation of external radiation dose to caregivers of patients treated with radioiodine after thyroidectomy.
Jeong KH; Jung JW; Kim CB; Ahn BC; Lee HK; Yoo SJ; Day O; Lee JK
Health Phys; 2014 Apr; 106(4):466-74. PubMed ID: 24562067
[TBL] [Abstract][Full Text] [Related]
7. Measurement of radiation exposure in relatives of thyroid cancer patients treated with (131)I.
Ramírez-Garzón YT; Ávila O; Medina LA; Gamboa-deBuen I; Rodríguez-Laguna A; Buenfil AE; Ruíz-Trejo C; Estrada E; Brandan ME
Health Phys; 2014 Nov; 107(5):410-6. PubMed ID: 25271931
[TBL] [Abstract][Full Text] [Related]
8. Correction factors for more accurate estimates of exposure rates near radioactive patients: experimental, point, and line source models.
Willegaignon J; Guimarães MI; Stabin MG; Sapienza MT; Malvestiti LF; Marone MM; Sordi GM
Health Phys; 2007 Dec; 93(6):678-88. PubMed ID: 17993848
[TBL] [Abstract][Full Text] [Related]
9. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
10. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
Al-Haj AN; Lagarde CS; Lobriguito AM
Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
[TBL] [Abstract][Full Text] [Related]
11. [Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant iodine radiotherapy].
Chaś J; Kowalczyk A; Siekierzyński M; Dziuk E; Janiak MK
Wiad Lek; 2001; 54 Suppl 1():312-20. PubMed ID: 12182042
[TBL] [Abstract][Full Text] [Related]
12. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.
Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK
Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
14. [Is the post-therapeutic dosimetry of patients with short-term hospitalization after 131I therapy sufficiently reliable?].
Körber C; Schneider P; Hänscheid H; Köck PR; Reiners C
Nuklearmedizin; 2000; 39(1):9-12. PubMed ID: 10726251
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
[TBL] [Abstract][Full Text] [Related]
16. 131I effective half-life and dosimetry in thyroid cancer patients.
Remy H; Borget I; Leboulleux S; Guilabert N; Lavielle F; Garsi J; Bournaud C; Gupta S; Schlumberger M; Ricard M
J Nucl Med; 2008 Sep; 49(9):1445-50. PubMed ID: 18703593
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive dose reconstruction methodology for former rocketdyne/atomics international radiation workers.
Boice JD; Leggett RW; Ellis ED; Wallace PW; Mumma M; Cohen SS; Brill AB; Chadda B; Boecker BB; Yoder RC; Eckerman KF
Health Phys; 2006 May; 90(5):409-30. PubMed ID: 16607174
[TBL] [Abstract][Full Text] [Related]
18. Use of a voxel phantom as a source and a second voxel phantom as a target to calculate effective doses in individuals exposed to patients treated with 131I.
de Carvalho AB; Hunt J; Silva AX; Garcia F
J Nucl Med Technol; 2009 Mar; 37(1):53-6. PubMed ID: 19223425
[TBL] [Abstract][Full Text] [Related]
19. Unexpected dose to the daughter of a patient treated with iodine-131 for hyperthyroidism.
Molyvda-Athanasopoulou E; Karaveli M; Chatzigiannaki A; Gotzamani-Psarrakou A
Hell J Nucl Med; 2007; 10(3):175-6. PubMed ID: 18084660
[TBL] [Abstract][Full Text] [Related]
20. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.
Modarresifar H; Almodovar S; Bass WB; Ojha B
Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
